LY294002, a morpholine-containing compound designed based on the flavonoid quercetin, is a potent and cell-permeable PI3K inhibitor, inhibiting PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively. Additionally, it inhibits BET (for example, BRD2, BRD3, and BRD4). It is more stable in solutions than the PI3K inhibitor Wortmannin. By acting on the ATP binding site of the catalytic subunit of PI3K, LY294002 is selective against p110α, p110β, p110γ and p110δ.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.